As part of our series focussing on medicines available in Australia, we have added a product review which outlines the pharmacology, clinical characteristics and clinical trial data of epcoritamab for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy in adult patients.
It also provides commentary and guidance from Associate Professor Gareth Gregory, Director of Haematology Research at Fiona Stanley Hospital and Associate Professor at Monash University.
Please login below to download this issue (PDF)